Report on the global market for breast cancer diagnostics and drug technologies

Jun 26 2012

Breast Cancer Diagnostic and Drug market are recovering after significant slowdown during the global recession. Having accurate market data and analysis will be essential to companies seeking to compete on the global stage as the market reemerges into success. With premium market research from the world's leading publishers, Global Information Inc. helps businesses stay on the cutting edge with the best forecasts, research, and analyses.

Breast Cancer Diagnostic and Drug Technologies: Global Markets

The global market for breast cancer diagnostics and drug technologies shrank significantly in 2011. The predictive breast cancer diagnostic and drug technology market was valued at $23.4 billion in 2010 and came down to $21.2 billion in 2011, while the Breast cancer drug market size reached $12.7 billion in 2010 and came down to $10.2 billion in 2011. The only market to show modest growth was the quantitative immunofluorescence market, which reached $5.7 billion in 2010 and $5.9 billion in 2011 respectively. This market also shows the biggest growth potential, with forecast CAGR of 3.1% by 2016, while breast cancer drugs will reach $11.2 billion by 2016 at a CAGR of 1.9%.

In their new report "Breast Cancer Diagnostic and Drug Technologies: Global Markets", BCC offers a comprehensive review of emerging breast cancer personalized and predictive diagnostic tests, particularly with regard to companion tests, tumor markers and gene profiling assays relevant for breast cancer prognosis and diagnosis; including SWOT analysis and market review. The report also reviews the current state of the companion diagnostics industry and the new technologies in assay development, and describes an overview of major biotechnology and pharmaceutical companies involved in developing innovative, targeted breast cancer treatments. In addition, the report also provides information regarding the less-developed sectors of this market and presents a list of current companies that have new predictive testing products and drugs in development for breast cancer.

An Executive Summary of this analysis and a free sample of the full report are available at http://www.giiresearch.com/report/bc245536-breast-cancer-diagnostic-drug-technologies-global.html

Breast Cancer Partnering 2007-2012

"Breast Cancer Partnering 2007-2012" provides access to the breast cancer partnering deals and agreements entered into by the world's leading healthcare companies, including analysis by industry sector, stage of development, and technology type. The report contains over 250 links to online copies of actual breast cancer deals and contract documents, offering details insight press releases do not disclose.

The report includes a comprehensive directory of breast cancer partnering deals signed and announced since 2007. Leading breast cancer deals are listed by value, industry sector, Stage of development at signing, Deal component and technology type.

An Executive Summary of this analysis and a free sample of the full report are available at http://www.giiresearch.com/report/wild233895-breast-cancer-partnering-2007-2012.html

SOURCE Global Information, Inc.